Table 3.
Univariate Analysis Of The Association Between Patients’ Characteristics And T790M Status
| Characteristics | T790M Status | p-Value | |||
|---|---|---|---|---|---|
| Positive | Negative | ||||
| Gender | Male | 20(51.28%) | 19(48.72%) | 0.635 | |
| Female | 37(56.06%) | 29(43.94%) | |||
| Primary site | Left lung | 25(56.82%) | 19(43.18%) | 0.724 | |
| Right lung | 32(53.33%) | 28(46.67%) | |||
| Initial EGFR-TKI | Gefitinib | 39(65.0%) | 21(35.0%) | 0.018 | |
| Icotinib | 15(40.54%) | 22(59.46%) | |||
| EGFR mutation status before TKI | Exon 19 deletions | 36(72.0%) | 14(28.0%) | 0.036 | |
| Exon 21 L858R | 12(44.44%) | 15(55.56%) | |||
| Other mutation | 1(33.33%) | 2(66.67%) | |||
| EGFR mutation status after TKI | Exon 19 deletion | 24(64.86%) | 13(35.14%) | =0.001 | |
| Exon 21 L858R | 13(61.9%) | 8(38.1%) | |||
| No common mutation (Exon 19 deletion and Exon 21 L858R) | 4(18.18%) | 19(81.82%) | |||
| Response of initial TKI | PR | 25(75.76%) | 8(24.24%) | 0.023 | |
| SD | 21(50%) | 21(50%) | |||
| Metastasis site | Lung | Yes | 50(54.35%) | 42(45.65%) | 0.990 |
| No | 6(54.55%) | 5(45.45%) | |||
| Bone | Yes | 29(58%) | 21(42%) | 0.472 | |
| No | 27(50.94%) | 26(49.06%) | |||
| Brain | Yes | 20(62.5%) | 12(37.5%) | 0.266 | |
| No | 36(50.7%) | 35(49.3%) | |||
| Other | Yes | 7(36.84%) | 12(63.16%) | 0.089 | |
| No | 49(58.33%) | 35(41.67%) | |||
| Treatment before TKI | Operation | Yes | 7(41.18%) | 10(58.82%) | 0.228 |
| No | 48(57.14%) | 36(42.86%) | |||
| Chemotherapy | Yes | 26(52%) | 24(48%) | 0.274 | |
| No | 29(63.04%) | 17(36.96%) | |||